Tsuda M, Asaka M, Kato M, Matsushima R, Fujimori K, Akino K, et al. Effect on Helicobacter pylori eradication therapy against gastric cancer in Japan. Helicobacter. 2017. https://doi.org/10.1111/hel.12415.

Article  PubMed  PubMed Central  Google Scholar 

Kamada T, Satoh K, Itoh T, Ito M, Iwamoto J, Okimoto T, et al. Evidence-based clinical practice guidelines for peptic ulcer disease 2020. J Gastroenterol. 2020;56(4):303–22.

Article  Google Scholar 

Yoshida M, Kinoshita Y, Watanabe M, Sugano K. JSGE clinical practice guidelines 2014: standards, methods, and process of developing the guidelines. J Gastroenterol. 2014;50(1):4–10.

Article  PubMed  Google Scholar 

Neumann I, Letelier LM, Rada G, Claro JC, Martin J, Howden CW, et al. Comparison of different regimens of proton pump inhibitors for acute peptic ulcer bleeding. Cochrane Database Syst Rev. 2013;2013(6):CD007999.

PubMed  PubMed Central  Google Scholar 

Jian Z, Li H, Race NS, Ma T, Jin H, Yin Z. Is the era of intravenous proton pump inhibitors coming to an end in patients with bleeding peptic ulcers? Meta-analysis of the published literature. Br J Clin Pharmacol. 2016;82(3):880–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sgourakis G, Chatzidakis G, Poulou A, Malliou P, Argyropoulos T, Ravanis G, et al. High-dose vs. low-dose proton pump inhibitors post-endoscopic hemostasis in patients with bleeding peptic ulcer. A meta-analysis and meta-regression analysis. Turk J Gastroenterol. 2018;29(1):22–31.

Article  PubMed  PubMed Central  Google Scholar 

Geeratragool T, Kaosombatwattana U, Boonchote A, Chatthammanat S, Preechakawin N, Srichot J, et al. Comparison of vonoprazan versus intravenous proton pump inhibitor for prevention of high-risk peptic ulcers rebleeding after successful endoscopic hemostasis: a multicenter randomized noninferiority trial. Gastroenterology. 2024;167(4):778-87 e3.

Article  CAS  PubMed  Google Scholar 

Pattarapuntakul T, Wong T, Wetwittayakhlang P, Netinatsunton N, Keeratichananont S, Kaewdech A, et al. Efficacy of vonoprazan vs. intravenous proton pump inhibitor in prevention of re-bleeding of high-risk peptic ulcers: a randomized controlled pilot study. J Clin Med. 2024. https://doi.org/10.3390/jcm13123606.

Article  PubMed  PubMed Central  Google Scholar 

Sugimoto M, Murata M. Differences and trends in worldwide clinical guidelines for Helicobacter pylori infection. Transl Gastroenterol Hepatol. 2026;11:47.

Article  PubMed  PubMed Central  Google Scholar 

Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol. 2004;99(9):1833–55.

Article  PubMed  Google Scholar 

Sugimoto M, Furuta T, Shirai N, Kodaira C, Nishino M, Ikuma M, et al. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter. 2007;12(4):317–23.

Article  CAS  PubMed  Google Scholar 

Kagami T, Sahara S, Ichikawa H, Uotani T, Yamade M, Sugimoto M, et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther. 2016;43(10):1048–59.

Article  CAS  PubMed  Google Scholar 

Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65(9):1439–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sue S, Shibata W, Sasaki T, Kaneko H, Irie K, Kondo M et al (2018) Randomized trial of Vonoprazan- Versus PPI-based third-line triple therapy with sitafloxacin for Helicobacter pylori. J Gastroenterol Hepatol

Hojo M, Asaoka D, Takeda T, Shimada Y, Matsumoto K, Matsumoto K, et al. Randomized controlled study on the effects of triple therapy including vonoprazan or rabeprazole for the second-line treatment of Helicobacter pylori infection. Therap Adv Gastroenterol. 2020;13:1756284820966247.

Article  CAS  Google Scholar 

Okimoto T, Ando T, Sasaki M, Ono S, Kobayashi I, Shibayama K, et al. Antimicrobial-resistant Helicobacter pylori in Japan: report of nationwide surveillance for 2018–2020. Helicobacter. 2024;29(1):e13028.

Article  CAS  PubMed  Google Scholar 

Ma Q, Li H, Liao J, Cai Z, Zhang B. Tailored therapy for Helicobacter pylori eradication: a systematic review and meta-analysis. Front Pharmacol. 2022;13:908202.

Article  PubMed  PubMed Central  Google Scholar 

Tsuda M, Watanabe Y, Oikawa R, Watanabe R, Higashino M, Kubo K, et al. Clinical evaluation of a novel molecular diagnosis kit for detecting Helicobacter pylori and clarithromycin-resistant using intragastric fluid. Helicobacter. 2022;27(6):e12933.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Isomoto H, Shimoyama T, Ito M, Osaki T, Toyoshima O, Matsuzaki J, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2024 revised edition. J Gastroenterol. 2024. https://doi.org/10.1007/s00535-026-02379-4.

Article  Google Scholar 

Kawai T, Yamagishi T, Yagi K, Kataoka M, Kawakami K, Sofuni A, et al. Tailored eradication therapy based on fecal Helicobacter pylori clarithromycin sensitivities. J Gastroenterol Hepatol. 2008;23(Suppl 2):S171–4.

CAS  PubMed  Google Scholar 

Lee HJ, Kim JI, Cheung DY, Kim TH, Jun EJ, Oh JH, et al. Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance. J Infect Dis. 2013;208(7):1123–30.

Article  CAS  PubMed  Google Scholar 

Park CS, Lee SM, Park CH, Koh HR, Jun CH, Park SY, et al. Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance. Am J Gastroenterol. 2014;109(10):1595–602.

Article  CAS  PubMed  Google Scholar 

Hsieh MS, Kuo FC, Wu MC, Wang JW, Liu CJ, Chu NS, et al. Tailored susceptibility-guided therapy via gastric juice PCR for the first-line H. pylori eradication, a randomized controlled trial. J Formos Med Assoc. 2022;121(8):1450–7.

Article  CAS  PubMed  Google Scholar 

Liu L, Shi H, Shi Y, Wang A, Guo N, Li F, et al. Vonoprazan-based therapies versus PPI-based therapies in patients with H. pylori infection: systematic review and meta-analyses of randomized controlled trials. Helicobacter. 2024;29(3):e13094.

Article  CAS  PubMed  Google Scholar 

Murata M, Sugimoto M, Mizuno H, Kanno T, Satoh K. Clarithromycin versus metronidazole in first-line Helicobacter pylori triple eradication therapy based on resistance to antimicrobial agents: meta-analysis. J Clin Med. 2020. https://doi.org/10.3390/jcm9020543.

Article  PubMed  PubMed Central  Google Scholar 

Suzuki S, Gotoda T, Kusano C, Ikehara H, Ichijima R, Ohyauchi M, et al. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut. 2020;69(6):1019–26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chey WD, Megraud F, Laine L, Lopez LJ, Hunt BJ, Howden CW. Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: randomized clinical trial. Gastroenterology. 2022;163(3):608–19.

Article  CAS  PubMed  Google Scholar 

Furuta T, Yamade M, Higuchi T, Takahashi S, Ishida N, Tani S, et al. Expectations for the dual therapy with vonoprazan and amoxicillin for the eradication of H. pylori. J Clin Med. 2023. https://doi.org/10.3390/jcm12093110.

Article  PubMed  PubMed Central  Google Scholar 

Shinozaki S, Kobayashi Y, Osawa H, Sakamoto H, Hayashi Y, Lefor AK, et al. Effectiveness and safety of vonoprazan versus proton pump inhibitors for second-line Helicobacter pylori eradication therapy: systematic review and meta-analysis. Digestion. 2021;102(3):319–25.

Article  CAS  PubMed  Google Scholar 

Murakami K, Furuta T, Ando T, Nakajima T, Inui Y, Oshima T, et al. Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan. J Gastroenterol. 2013;48(10):1128–35.

Article  PubMed  Google Scholar 

Furuta T, Sugimoto M, Kodaira C, Nishino M, Yamade M, Uotani T, et al. Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan. J Gastroenterol Hepatol. 2014;29(3):487–93.